“Russia has developed two personalized mRNA cancer vaccines that represent a genuine and significant medical development. The first, Enteromix, developed by the Federal Medical and Biological Agency, targets colorectal cancer and completed Phase I trials with 48 patients in 2025, reporting a 100% immune response rate and tumor growth…”
Plain restatementRussia has announced two personalized therapeutic mRNA cancer vaccines: Enteromix (FMBA, colorectal cancer, Phase I completed 2025 with 48 patients, reporting strong immune response and tumor reductions) and Neoonkovak (Gamaleya Centre, melanoma, first patient treated April 2026). Both are planned to be free under Russian state insurance. Independent experts caution data is early, small, and not peer reviewed. Other mRNA cancer vaccine programs exist at Moderna, BioNTech, and the UK NHS.
Russia has genuinely developed two personalized mRNA cancer vaccines: Enteromix for colorectal cancer, and Neoonkovak for melanoma. A Phase I trial of Enteromix with 48 patients ran from June to December 2025, and the first Neoonkovak patient was treated in April 2026. Russian officials say both will be free for citizens under state insurance. The main misleading element in the viral claim is the 60 to 80 percent tumor reduction figure. IBTimes UK, one of the cited sources, attributes that number to preclinical animal-model testing, not to the 48-patient human trial, though some other outlets present it as a human result. No peer-reviewed publication for either vaccine has been located, and the "JAMA Network" attribution could not be verified. Independent oncologists have said the data is promising but too early and too small to validate the vaccines by international standards without Phase II and III trials.
Russia has [drifted from the evidence:] developed two personalized mRNA cancer vaccines [drifted from the evidence:] that represent a genuine and significant medical development. The first, Enteromix, [drifted from the evidence:] developed by the Federal Medical and Biological Agency, targets colorectal cancer [drifted from the evidence:] and completed Phase I [drifted from the evidence:] trials with 48 patients [drifted from the evidence:] in 2025, reporting [drifted from the evidence:] a 100% immune response [drifted from the evidence:] rate and tumor [drifted from the evidence:] growth reductions [drifted from the evidence:] of 60 to 80% in some cases. The second, Neoonkovak, [drifted from the evidence:] developed by the Gamaleya Centre, [drifted from the evidence:] targets melanoma [drifted from the evidence:] and treated its first patient [drifted from the evidence:] in April 2026. Both [drifted from the evidence:] vaccines are [drifted from the evidence:] therapeutic and personalized. Russia's Health Ministry has proposed adding these treatments to [drifted from the evidence:] compulsory insurance starting in 2026, making them free [drifted from the evidence:] for Russian [drifted from the evidence:] citizens. Independent [drifted from the evidence:] oncologists caution [drifted from the evidence:] the Phase I data is small and not peer reviewed, [drifted from the evidence:] with Phase II and III trials needed. The broader race includes Moderna, BioNTech, and the [drifted from the evidence:] UK's NHS.
Russia has [added by the neutral restatement:] announced two personalized [added by the neutral restatement:] therapeutic mRNA cancer vaccines: Enteromix [added by the neutral restatement:] (FMBA, colorectal cancer, Phase I [added by the neutral restatement:] completed 2025 with 48 patients, reporting [added by the neutral restatement:] strong immune response and tumor reductions) [added by the neutral restatement:] and Neoonkovak (Gamaleya Centre, melanoma, first patient [added by the neutral restatement:] treated April 2026). Both are [added by the neutral restatement:] planned to [added by the neutral restatement:] be free [added by the neutral restatement:] under Russian [added by the neutral restatement:] state insurance. Independent [added by the neutral restatement:] experts caution data is [added by the neutral restatement:] early, small, and not peer reviewed. [added by the neutral restatement:] Other mRNA cancer vaccine programs exist at Moderna, BioNTech, and the [added by the neutral restatement:] UK NHS.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- Both vaccines exist and are named as stated.
- Enteromix is developed by FMBA (with collaborating institutes) and targets colorectal cancer.
- Neoonkovak is developed by the Gamaleya Centre and targets melanoma.
- The Enteromix Phase I trial with 48 patients occurred in 2025 (June to December).
- Neoonkovak's first patient was treated in early April 2026.
- Both are therapeutic (not preventive) and personalized to tumor genetics.
- Russian officials have said the vaccines will be provided free to Russian citizens under state insurance.
- Independent oncologists have called for caution pending peer review and larger Phase II/III trials.
- Moderna, BioNTech, and the UK NHS all have publicly known mRNA cancer vaccine programs.
- Ambiguity around the "60 to 80% tumor reduction" figure. The claim attaches this figure to the Phase I human trial, but IBTimes UK, the outlet cited by the post, attributes it to preclinical animal-model testing. Other outlets do report the figure as a Phase I human result. This is a possible species-extrapolation or context-conflation problem depending on which source is authoritative, and it is currently unresolved in publicly available reporting.
- The "100% immune response rate" originates from FMBA statements, not from a peer-reviewed publication, and reflects an unpublished official announcement rather than independently validated data.
- The framing "genuine and significant medical development" is stronger than the evidence supports at present, given no peer-reviewed data and Phase I design that is not intended to prove efficacy.
- Whether JAMA Network actually published anything about these vaccines. No such article was located.
- Whether the 60 to 80 percent tumor reduction is a preclinical animal figure, a human Phase I finding, or both.
- Full methodology of the Phase I trial (registration number, protocol, endpoint definitions, adverse event data) is not publicly available in indexed sources.
- Whether inclusion in Russia's compulsory insurance program has been formally enacted or only proposed.
Multiple secondary sources confirm the existence of both vaccines and the broad outline of the claim. Phase-1 clinical trials began in June 2025, enrolling 48 volunteers for Enteromix, a personalized mRNA colorectal cancer vaccine developed by Russia's FMBA. The scientific journey of Enteromix began with a Phase I clinical trial conducted between June and December 2025, involving just 48 volunteers with colorectal cancer, was designed primarily to assess safety and immune response, not to prove efficacy. Initial Phase I trials began in June 2025 with 48 colorectal cancer patients. Results showed tumor reduction of 60–80% in some cases, with complete elimination in early-stage patients. However, other reporting attributes the 60 to 80 percent tumor reduction figure to preclinical (animal model) testing, not to the human Phase I trial. According to IBTimes UK, Enteromix from the Federal Medical and Biological Agency, completed pre-clinical testing last year showing safety and effectiveness in reducing tumour size and slowing growth in models by 60 to 80 per cent in some assessments . This creates a genuine ambiguity in the source reporting: some outlets present the 60 to 80 percent figure as a Phase I human result; others present it as preclinical animal-model data. For Neoonkovak, In early April a 60-year-old resident of the Kursk region with skin melanoma became the first recipient of Neoonkovak, a treatment created using information from their own tumour antigens to train the immune system. Alexander Ginzburg, director of the Gamaleya Centre in a EA Daily report, said 'the new antitumor mRNA vaccine Neoonkovak gave the first results of treatment', with observed shifts in cytokine production indicating an immune response. On availability and policy: In 2025, the Russian Federal Medical-Biological Agency announced Enteromix, a personalised mRNA vaccine for colorectal cancer, with Phase I trials starting in June 2025. Then, in April 2026, the Gamaleya Centre treated the first patient with Neoonkovak, a personalised melanoma mRNA vaccine. Russian officials say the treatments will be free for citizens under state insurance. On evidence quality: independent experts have consistently urged caution. Exaggerated claims about Russia's cancer vaccine Enteromix sweep across Africa , and cited experts have said "I can find no peer-reviewed academic evidence of this vaccine Enteromix being tested in human clinical trials" . A review notes that The current lack of peer-reviewed scientific publications limits transparency and independent scrutiny. The relatively small sample size in the Phase I trial restricts broader inferences.
Complete reasoning
The reply receipt is formatted for pasting into the thread where the claim is circulating.
Compact share page: verify.trueseeker.com/s/2607c9eb22d2/IGeZs-_qTZ15Z2PEQM1koC-
Ask this case
Answers come only from the case file above; nothing is added.
Do these two Russian cancer vaccines actually exist?
Yes. Enteromix, developed by Russia's Federal Medical and Biological Agency for colorectal cancer, and Neoonkovak, developed by the Gamaleya Centre for melanoma, are both real and named as stated in the claim.
Is the 60 to 80 percent tumor reduction figure from human trials?
This is unresolved. IBTimes UK, one of the sources cited in the original claim, attributes that figure to preclinical animal-model testing, not to the 48-patient human trial. Other outlets present it as a human result. The case file identifies this ambiguity as the main misleading element.
Has the 100 percent immune response rate been independently verified?
No. That figure comes from an official announcement by Russia's FMBA and has not appeared in any peer-reviewed publication that investigators were able to locate.
Will these vaccines really be free for Russian citizens?
Russian officials have stated both vaccines will be provided free under state insurance, but the case file notes it is uncertain whether this has been formally enacted or remains a proposal.
Do the results meet international scientific standards?
Not yet. No peer-reviewed publications for either vaccine have been located, the Phase I trial was designed to assess safety rather than prove effectiveness, and independent oncologists say Phase II and III trials are needed before broader conclusions can be drawn.